Enterprise Value
-239M
Cash
373.3M
Avg Qtr Burn
N/A
Short % of Float
7.33%
Insider Ownership
14.22%
Institutional Own.
88.45%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Approved Update | |
AMX0035 Details Progressive supranuclear palsy | Phase 3 Data readout | |
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Phase 3 Update | |
Avexitide Details Hyperinsulinism, Post-Bariatric Hypoglycemia, Congenital Hyperinsulinism | Phase 3 Initiation | |
Phase 2 Data readout | ||
AMX0035 Details Alzheimer's disease | Phase 2 Update | |
AMX0114 Details Amyotrophic lateral sclerosis | Phase 1 Initiation |